JP2019510745A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510745A5
JP2019510745A5 JP2018544455A JP2018544455A JP2019510745A5 JP 2019510745 A5 JP2019510745 A5 JP 2019510745A5 JP 2018544455 A JP2018544455 A JP 2018544455A JP 2018544455 A JP2018544455 A JP 2018544455A JP 2019510745 A5 JP2019510745 A5 JP 2019510745A5
Authority
JP
Japan
Prior art keywords
composition
patient
lactose
linoleic acid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018544455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510745A (ja
JP7125350B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/054526 external-priority patent/WO2017144725A1/en
Publication of JP2019510745A publication Critical patent/JP2019510745A/ja
Publication of JP2019510745A5 publication Critical patent/JP2019510745A5/ja
Application granted granted Critical
Publication of JP7125350B2 publication Critical patent/JP7125350B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018544455A 2016-02-26 2017-02-27 ラクトース不耐性を処置する方法 Active JP7125350B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300376P 2016-02-26 2016-02-26
US62/300,376 2016-02-26
PCT/EP2017/054526 WO2017144725A1 (en) 2016-02-26 2017-02-27 Methods of treating lactose intolerance

Publications (3)

Publication Number Publication Date
JP2019510745A JP2019510745A (ja) 2019-04-18
JP2019510745A5 true JP2019510745A5 (cg-RX-API-DMAC7.html) 2020-04-09
JP7125350B2 JP7125350B2 (ja) 2022-08-24

Family

ID=58162625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544455A Active JP7125350B2 (ja) 2016-02-26 2017-02-27 ラクトース不耐性を処置する方法

Country Status (6)

Country Link
US (1) US20190046490A1 (cg-RX-API-DMAC7.html)
EP (1) EP3419616A1 (cg-RX-API-DMAC7.html)
JP (1) JP7125350B2 (cg-RX-API-DMAC7.html)
CA (1) CA3014575A1 (cg-RX-API-DMAC7.html)
MA (1) MA43682A (cg-RX-API-DMAC7.html)
WO (1) WO2017144725A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2396081T3 (en) 2009-02-16 2017-07-10 Nogra Pharma Ltd Alkylamide compounds and applications
KR102067848B1 (ko) 2012-02-09 2020-01-17 노그라 파마 리미티드 섬유증의 치료 방법
RS66513B1 (sr) 2019-02-08 2025-03-31 Nogra Pharma Ltd Postupak pripreme 3-(4'-aminofenil)-2-metoksipropionske kiseli-ne i njenih analoga i intermedijera

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
JP2001525364A (ja) 1997-12-12 2001-12-11 パーデュー・リサーチ・ファンデーション 糖尿病を治療する方法及び組成物
AU2002357729A1 (en) * 2001-11-16 2003-06-10 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
EP1719543A1 (en) * 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
WO2007096148A1 (en) * 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
AU2013248397A1 (en) 2012-04-18 2014-10-02 Nogra Pharma Limited Methods of treating lactose intolerance
WO2013168438A1 (ja) * 2012-05-10 2013-11-14 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
MX2015013511A (es) * 2013-03-26 2016-06-28 Lipid Therapeutics Gmbh Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitis ulcerosa.

Similar Documents

Publication Publication Date Title
JP6077857B2 (ja) β−ヒドロキシ−β−メチル酪酸塩(HMB)の改善された投与方法
CN111227044B (zh) 一种乳制品、其制备方法及医药应用
TW200902040A (en) Probiotics in a pre-and/or post-surgical environment
EP3305083A1 (en) Lipid-containing compositions and methods of use thereof
TW200815023A (en) Prevention and treatment of otitis media
US9314444B2 (en) Composition and method for treatment of NASH
CN120131635A (zh) 包含尿石素化合物的组合物
JP7336994B2 (ja) 温熱療法治療を増強するための組成物および方法
US20090203780A1 (en) Use of a Polyunsaturated Fatty Acid Compound
JP2019510745A5 (cg-RX-API-DMAC7.html)
CN1946412B (zh) 炎性肠病的预防和/或治疗剂
Gaby Alternative treatments for rheumatoid arthritis
CN110403014B (zh) 一种能抑制食欲的营养粉及其制备方法与应用
Scholz The role of nutrition in the etiology of inflammatory bowel disease
CN107467193B (zh) 一种以羊奶为基础的粉剂全营养特殊医学用途配方食品及其制备方法
JP4603269B2 (ja) 生理活性のない高分散型基質上で乾燥させた馬乳濃縮物の使用
WO2019181822A1 (ja) エネルギー代謝促進用組成物
WO2009083643A2 (en) Composition for treating sterile inflammation
JP5823695B2 (ja) 肝機能障害予防剤
CN1917868A (zh) 包含l-丝氨酸、l-异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物
Holečková et al. Effect of a 3-month nutritional intervention with a high protein omega 3-enriched oral nutritional supplement on selected anthropometric and laboratory parameters and muscle strength in oncology patients
ES2302396B1 (es) Alimento funcional a base de un producto lacteo fermentado liquido y acido linoleico conjugado.
WO2018207122A1 (en) Composition to prevent intestinal damage
KR101402456B1 (ko) 피톤치드 및 공액리놀레산을 포함하는 항비만용 조성물
JP2006104080A (ja) 痛風と尿酸による血流障害の予防又は治療効果のある組成物及び健康食品。